The main risk is not reactor science; it is commercial conversion. NuScale has a rare regulatory asset, but 2031 value still depends on a small set of external gates: one definitive U.S. structure, continued Romania funding, supplier readiness, site-specific approvals, and proof that NuScale keeps enough economics after partners, customers, and future
dilution take their share.